Anixa Biosciences, Inc. (NASDAQ:ANIX) CFO Acquires $19,971.35 in Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX) CFO Michael Catelani acquired 9,289 shares of the company’s stock in a transaction dated Wednesday, January 15th. The stock was acquired at an average price of $2.15 per share, for a total transaction of $19,971.35. Following the completion of the purchase, the chief financial officer now directly owns 44,500 shares of the company’s stock, valued at $95,675. This trade represents a 26.38 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Anixa Biosciences Stock Up 7.0 %

Shares of ANIX opened at $2.28 on Thursday. The stock’s 50-day moving average price is $2.86 and its 200 day moving average price is $3.03. The firm has a market capitalization of $73.37 million, a price-to-earnings ratio of -5.85 and a beta of 0.82. Anixa Biosciences, Inc. has a 12-month low of $2.07 and a 12-month high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Friday, January 10th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. Equities research analysts expect that Anixa Biosciences, Inc. will post -0.42 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on ANIX shares. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price target on shares of Anixa Biosciences in a research report on Tuesday, November 19th. D. Boral Capital reiterated a “buy” rating and set a $10.00 target price on shares of Anixa Biosciences in a research note on Tuesday.

Hedge Funds Weigh In On Anixa Biosciences

A number of hedge funds have recently made changes to their positions in ANIX. Concorde Asset Management LLC acquired a new stake in shares of Anixa Biosciences during the 2nd quarter valued at about $31,000. Virtu Financial LLC bought a new position in Anixa Biosciences during the third quarter worth about $34,000. Westside Investment Management Inc. boosted its holdings in Anixa Biosciences by 151.8% during the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after purchasing an additional 21,100 shares in the last quarter. Tyler Stone Wealth Management grew its stake in shares of Anixa Biosciences by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after purchasing an additional 21,008 shares during the period. Finally, International Assets Investment Management LLC raised its holdings in shares of Anixa Biosciences by 170.0% in the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after buying an additional 23,800 shares in the last quarter. Institutional investors and hedge funds own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.